CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: January 3, 2017
Result type: Reports
Project Number: SR0512-000
Product Line: Reimbursement Review

Generic Name: abobotulinumtoxinA

Brand Name: Dysport Therapeutic

Manufacturer: IPSEN Biopharmaceuticals Canada, Inc.

Therapeutic Area: Cervical dystonia

Indications: Cervical dystonia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 26, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions